XTX Topco Ltd Makes New Investment in Seer, Inc. (NASDAQ:SEER)

XTX Topco Ltd acquired a new stake in shares of Seer, Inc. (NASDAQ:SEER) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 62,190 shares of the company’s stock, valued at approximately $123,000. XTX Topco Ltd owned about 0.10% of Seer at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of SEER. Point72 DIFC Ltd bought a new position in Seer during the 2nd quarter valued at approximately $35,000. Cubist Systematic Strategies LLC bought a new position in shares of Seer during the second quarter valued at approximately $133,000. Acadian Asset Management LLC raised its holdings in shares of Seer by 35.5% during the second quarter. Acadian Asset Management LLC now owns 1,802,106 shares of the company’s stock valued at $3,024,000 after acquiring an additional 472,283 shares in the last quarter. AQR Capital Management LLC bought a new stake in Seer in the second quarter valued at $30,000. Finally, GSA Capital Partners LLP increased its position in Seer by 194.9% during the 3rd quarter. GSA Capital Partners LLP now owns 127,868 shares of the company’s stock valued at $252,000 after purchasing an additional 84,515 shares during the period. 75.20% of the stock is currently owned by hedge funds and other institutional investors.

Seer Trading Down 0.4 %

Shares of NASDAQ SEER opened at $2.31 on Friday. The firm has a fifty day simple moving average of $2.24 and a two-hundred day simple moving average of $1.93. The firm has a market capitalization of $136.21 million, a PE ratio of -1.78 and a beta of 1.58. Seer, Inc. has a 12 month low of $1.51 and a 12 month high of $2.63.

About Seer

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.